Biohaven Completes Enrollment in Phase 2 Study of Taldefgrobep Alfa
Biohaven announced the completion of enrollment in a Phase 2 proof-of-concept study with its myostatin-activin pathway inhibitor, taldefgrobep alfa, which offers the potential to achieve high-quality weight loss in people living with obesity. Topline data from the study are expected in 2H 2026.
